High-Risk HFrEF: Who Will Benefit Most from Novel Therapies? - a podcast by ReachMD

CME credits: 0.25

Valid until: 08-02-2023

Claim your CME credit at https://reachmd.com/programs/cme/high-risk-hfref-who-will-benefit-most-from-novel-therapies/13297/

Have you started using newly approved therapies when caring for your patients with heart failure with reduced ejection fraction (HFrEF)? Tune in to hear Drs. Javed Butler and Shelley Zieroth discuss strategies you can use to determine the best treatment approaches for your most challenging patients. A 3D mechanism of action animation is included to help you understand the workings of novel classes of agents in heart failure. Make sure you get with the guidelines, because guideline-directed medical therapy really does work.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD